Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WL3H
|
|||
| Former ID |
DIB006248
|
|||
| Drug Name |
LY03005
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z] | Phase 3 | [1] | |
| Company |
Luye america pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H31NO3
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)C(CN(C)C)C3(CCCCC3)O
|
|||
| InChI |
1S/C24H31NO3/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24/h7-14,22,27H,4-6,15-17H2,1-3H3
|
|||
| InChIKey |
QKYBZJLEMOZFFU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 916918-80-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04853407) A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.